U.S. stock futures were trading under the flatline in early Wednesday premarket activity as energy prices climbed above $100 a barrel and market participants prepared for incoming inflation figures that could strengthen expectations of a Federal Reserve interest-rate increase later this month.
At 06:13 ET (10:13 GMT), S&P 500 futures were down 19 points, or 0.3%. Nasdaq 100 futures had fallen 134 points, or 0.5%, while Dow Jones futures slipped 206 points, or 0.4%.
Higher crude prices have heightened inflation worries, which in turn can complicate the Fed's policy outlook. Rising energy costs tend to flow through to broader consumer and business prices, and the prospect of stronger inflation can make investors more cautious about growth stocks that are sensitive to interest-rate moves.
Below are the most notable premarket movers and the company-specific developments behind their price action.
Meta Platforms - AI product launch lifts shares
Meta Platforms' shares climbed 3.6% in premarket trading following the company's official launch on Tuesday evening of Muse, an autonomous artificial intelligence personal agent. The product is powered by Meta's Muse Spark model and is billed as capable of independently completing tasks such as booking travel, sending emails, filling out web forms and handling payments. Muse will be available on iOS, Android and via a dedicated web application.
The release also aligns with Meta's push to monetize its AI investments through a tiered subscription offering. The company introduced paid tiers priced at $20 and $100 per month as well as a free tier.
Evommune - trial failure weighs on stock
Shares of Evommune dropped 13.9% in premarket trading to $11.26 after the biotechnology company reported that its drug candidate EVO756 did not meet the primary and secondary endpoints in a Phase 2b study of adults with moderate-to-severe atopic dermatitis. The randomized, double-blind, placebo-controlled trial enrolled 121 adults and evaluated treatment over a 12-week period.
The trial's primary endpoint measured the percentage change in the Eczema Area and Severity Index score from baseline at Week 12, and the study did not achieve that target. In response, Evommune said it will not advance EVO756 for atopic dermatitis but intends to continue Phase 2b development of the same compound as a potential migraine prevention therapy.
Braze - results beat but outlook disappoints
Braze shares tumbled 11.5% before the market opened after the customer engagement software company posted fiscal second-quarter results that topped expectations on both the top and bottom lines but issued profit guidance that missed forecasts for the current quarter.
For fiscal Q2 2027, Braze reported adjusted earnings per share of $0.19, above the analyst consensus of $0.15. Revenue grew 26% year over year to $227.2 million, outpacing the expected $220.23 million. However, management guided fiscal third-quarter adjusted EPS to a range of $0.13 to $0.14. The midpoint of that guidance was roughly 15% to 16% below the analyst consensus of $0.16, and the weak outlook overshadowed the quarter's beat.
Investors also noted signs of moderating growth. Revenue growth decelerated to 26.2% in the second quarter from 30.2% in the first quarter, free cash flow margins declined sequentially, and customer growth showed signs of slowing. Canaccord was among the more constructive responses, raising its price target on Braze to $37 while maintaining a Buy rating and citing record free cash flow and strong billings growth.
NETGEAR - regulatory action benefits router maker
Shares of NETGEAR jumped 8.9% in premarket trade after the Federal Communications Commission formally banned the import of new consumer routers manufactured outside the United States. The agency cited national security risks tied to foreign supply chains and cybersecurity vulnerabilities. The restriction applies to new device models seeking FCC certification and could constrain product launches by many competitors that rely on overseas manufacturing.
NETGEAR had already secured a conditional FCC approval exemption that allows it to continue providing firmware updates and support for its existing router lineup while competitors adapt to the new rules. The company also reported momentum in its enterprise business, with 7.7% year-over-year growth and an all-time-high non-GAAP gross margin of 54.1% in its most recent quarter.
Taken together, the moves illustrate how macro crosswinds - in this case, rising oil prices and their implications for inflation - interact with company-specific catalysts to produce outsized premarket volatility. Market participants will be watching the pending inflation release for signals about the Fed's path, even as individual firms digest product launches, clinical trial readouts, regulatory shifts and forward guidance.